High-dose intravenous immunoglobulins: An approach to treat severe immune-mediated and autoimmune diseases of the skin

Journal of the American Academy of Dermatology

Volumn 44, Issue 6, 2001, Pages 1010-1024

  Rütter, Anita ^a   Luger, Thomas A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOMODULATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; REVIEW; SKIN DISEASE;

EID: 0035018252     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.112325     Document Type: Article

References (186)

1. Appropriate uses of human immunoglobulin in clinical practice: Memorand IUIS/WHO meeting
2. Arzneimittelprüflinien
3. Clinical uses of intravenous immunoglobulin
4. Intravenous immunoglobulin: A review
5. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinenaemia
6. Systemic and topical immunoglobulin treatment in immunocompromised patients
7. Use of high-dose intravenous immunoglobulins in pediatric hematology
8. Prevention of infection in patients with B cell defects: Focus on intravenous immunoglobulin
9. Efficacy of intravenous immunoglobulins in patients with advanced HIV-1 infection: A randomized clinical study
10. Clinical and immunologic effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients
11. Therapy with immunoglobulin of the HIV infection related idiopathic thrombocytopenia
12. Beneficial effects of intravenous immunoglobulins in AIDS
13. Immune globulin therapy in allogeneic bone marrow transplant: A critical review
14. Immunomodulation in allogeneic marrow transplantation: Use of intravenous immune globulin to suppress acute graft-versus-host disease
15. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery
16. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998
17. Manipulating the immune system with immune globulin
18. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases
19. Use of immune globulins in the prevention and treatment of infections
20. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig)
21. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
22. Possible mechanisms of intravenous immunoglobulin treatment in childhood idiopathic thrombocytopenic purpura (ITP)
23. Fc receptors in liver sinusoidal endothelial cells in NZB/W F1 lupus mice: A histological analysis using soluble immunoglobulin G-immune complexes and a monodonal antibody
24. Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia
25. Effect of intravenous immunoglobulin in immune thrombocytopenia
26. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases
27. Antiidiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin
28. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig
29. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
30. Modulation of complement-mediated immune damage by intravenous immune globulin
31. Pooled human IgG modulates cytokine production in lymphocytes and monocytes
32. Natural human IgG inhibits the production of tumor necrosis factor-alpha and interleukin-1 alpha through the Fc portion
33. Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use
34. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production
35. Human intravenous immunoglobulin modulates monokine production in vitro
36. Pooled human immunoglobulin inhibits IL-4 but not IFN-gamma or TNF-alpha secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen
37. Immunomodulatory effect of immunoglobulins
38. Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated
39. IgG induction of IL-1 receptor antagonist production by human monocytes
40. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations
41. Immunologically active proteins in intravenous immunoglobulin
42. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases
43. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use
44. Intravenous immunoglobulins and transforming growth factor beta
45. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
46. Adverse effects of intravenous immunoglobulin
47. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia: Detection of IgE antibodies to IgA
48. Selective IgA deficiency and systemic lupus erythematosus
49. Persistent and transient IgA deficiency in juvenile rheumatoid arthritis
50. Side-effects of intravenous immune globulins
51. Effect of high-dose intravenous immunoglobulin therapy on blood rheology
52. Acute renal failure following immunoglobulin therapy
53. Pinocytosis as the cause of sucrose nephrosis
54. Mannitol-induced acute renal failure
55. Acute renal failure resulting from intravenous immunoglobulin therapy
56. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin
57. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease
58. Hemolysis after high-dose intravenous Ig
59. Intravenous immune globulin and acute aseptic meningitis
60. Dermatological uses of high-dose intravenous immunoglobulin
61. Lupus nephritis: Update on pathogenesis and disease mechanisms
62. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins
63. The role of autoantibodies in the pathogenesis of lupus nephritis
64. Natural history and treatment of lupus nephritis
65. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
66. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: Report of 2 cases
67. Immunoglobulin therapy for systemic lupus erythematosus
68. Recurrent cerebral infarction and the antiphospholipid syndrome: Effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus
69. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study
70. Intravenous administration of immunoglobulins in systemic lupus erythematosus: Review of the literature and initial clinical experiences
71. Intravenous immunoglobulin administration to a patient with systemic lupus erythematosus and pneumococcal septicemia
72. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin
73. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus
74. Intravenous immune globulin for inducing remissions in systemic lupus erythematosus
75. Treatment of a case with pooled intravenous immunoglobulin as an alternative to immunosuppression
76. IgG therapy in systemic lupus erythematosus: Two case reports
77. Lupus refractory pleural effusion: Transient response to intravenous immunoglobulins
78. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease
79. Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins
80. Long-term i.v. Ig treatment in systemic lupus erythematosus
81. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis
82. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin
83. Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome
84. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome
85. Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus
86. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus
87. Inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis)
88. Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature
89. Polymyositis, dermatomyositis and inclusion-body myositis
90. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
91. Dermatomyositis
92. Immunopathology and treatment of polymyositis and dermatomyositis
93. Drug therapy in juvenile dermatomyositis: Follow-up study
94. The value of methotrexate in dermatomyositis
95. IGIV in neurology: Evidence and recommendations
96. Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis: An open trial in 15 patients
97. Juvenile dermatomyositis: Treatment with intravenous gammaglobulin
98. High-dose immunoglobulin therapy for a patient with dermatomyositis
99. Immunoglobulin therapy in inflammatory myopathies
100. Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis
101. High dosage intravenous gamma globulin therapy in juvenile dermatomyositis
102. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin
103. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: Clinical responses and effect on sIL-2R levels
104. Management of systemic sclerosis: The art and science
105. Pathophysiology of scleroderma: An update
106. Efficacy of intravenous immunoglobulins in sclerodermatomyositis
107. Intravenöse immunglobuline in der behandlung von autoimmunerkrankungen der haut
108. Disabling morphoea of childhood: Beneficial effect of intravenous immunoglobulin therapy
109. A case of pemphigus vulgaris showing reactivity with pemphigus antigens (Dsg1 and Dsg3) and desmocollins
110. Pemphigus: Past, present and future
111. Adhesion molecules. I: Keratinocyte-keratinocyte interactions: Cadherins and pemphigus
112. Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1
113. The new pemphigus variants
114. Pemphigus: A 20-year review of 107 patients treated with corticosteroids
115. Bullous pemphigoid and intravenous gammaglobulin
116. Intravenöse immunglobuline, ein wirksames und gut verträgliches additivum in der behandlung therapieresistenter autoimmundermatosen
117. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: Experience in six patients
118. High-dose intravenous immunoglobulins for immediate control of severe pemphigus
119. High-dosage intravenous gamma globulin: Therapeutic failure in pemphigus and pemphigoid
120. Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins
121. Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins
122. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: An evaluation of its use in 14 cases
123. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy
124. Intravenous immunoglobulins for pemphigus vulgaris: Adjuvant or first choice therapy?
125. Effects of intravenous gamma-globulin in pemphigus
126. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy
127. Conversion of pemphigoid gestationis to bullous pemphigoid: Two refractory cases high-lighting this association
128. Herpes gestationis: Persistent disease activity 11 years post partum
129. A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin
130. Identification of the epidermolysis bullosa acquisita antigen by LH 7.2 monoclonal antibody: Use in diagnosis
131. Epidermolysis bullosa acquisita antigen and the carboxy terminus of type VII collagen have a common immunolocalization to anchoring fibrils and lamina densa of basement membrane
132. Epidermolysis bullosa acquisita: Efficacy of high-dose intravenous immunoglobulins
133. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins
134. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita
135. 97-kDa linear IgA bullous dermatosis (LAD) antigen localizes to the lamina lucida of the epidermal basement membrane
136. A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies
137. Linear IgA bullous dermatosis in a patient with chronic renal failure: Response to intravenous immunoglobulin therapy
138. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: A clinical classification
139. Severe adverse cutaneous reactions to drugs
140. A case of toxic epidermal necrolysis treated with intravenous immunoglobulin
141. Cyclosporin in atopic dermatitis: A multicentre placebo-controlled study
142. Assembling the puzzle pieces in atopic inflammation
143. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis
144. Recent developments in the treatment of atopic eczema
145. High dose gammaglobulin treatment for atopic dermatitis
146. Intravenous immune globulin: An alternative therapy in steroid-dependent allergic diseases
147. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis
148. Job's syndrome: Recurrent, "cold," staphylococcal abscesses
149. Hypergammaglobulinaemia, antibody deficiency, autoimmune haemolytic anaemia, and nephritis in an infant with a familial lymphopenic immune defect
150. Hyper-IgE syndrome and H2-receptor blockade
151. Alpha-interferon treatment of patient with hyper IgE syndrome
152. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome
153. Nedocromil sodium selectively inhibits IgE and IgG4 production in human B cells stimulated with IL-4
154. Shifts in interleukin-4 and interferon-gamma production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis
155. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma
156. Asthma and selective immunoglobulin subclass deficiency: Improvement of asthma after immunoglobulin replacement therapy
157. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma
158. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: A double-blind, placebo-controlled, randomized trial
159. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria
160. Anti-FcepsilonRlalpha autoantibodies in autoimmune-mediated disorders: Identification of a structure-function relationship
161. Successful treatment of chronic urticaria with leukotriene antagonists
162. Chronic urticaria - Update
163. Chronic urticaria
164. Intravenous immunoglobulin in autoimmune chronic urticaria
165. Fate of coronary aneurysms in Kawasaki disease: Serial coronary angiography and long-term follow-up study
166. The immunopathogenesis and management of Kawasaki syndrome
167. Kawasaki disease
168. Kawasaki syndrome
169. High-dose intravenous gammaglobulin for Kawasaki disease
170. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome
171. The treatment of Kawasaki syndrome with intravenous gamma globulin
172. The immunoregulatory effects of IVIg in Kawasaki disease and other autoimmune diseases
173. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease
174. Pyoderma gangrenosum: Classification and management
175. Pyoderma gangrenosum and related disorders
176. Chlorambucil: An effective corticosteroid-sparing therapy for pyoderma gangrenosum
177. Efficacy of human intravenous immune globulin in pyoderma gangrenosum
178. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin
179. Post-traumatic pyoderma gangrenosum: Combination therapy with intravenous immunoglobulins and systemic corticosteroids
180. Erythema multiforme: A critical review of characteristics, diagnostic criteria, and causes
181. Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme
182. Recurrent erythema multiforme
183. Recurrent erythema multiforme: Clinical features and treatment in a large series of patients
184. Graft-versus-host disease
185. Intravenous immunoglobulins in bone marrow transplantation